GlassScriptPhysician profile
Timothy S Shaver
NPI 1275598674
$1,508.42
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $247 · 2021: $167 · 2022: $358 · 2023: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.88 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $399.03 | 2019-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $243.24 | 2022-2023 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $156.79 | 2019-2023 | Breztri |
| Lilly USA, LLC | $128.99 | 2020-2023 | Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $108.29 | 2019-2022 | |
| Abbott Laboratories | $81.43 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Ethicon US, LLC | $77.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.68 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.55 | 2021-2022 | |
| Pfizer INC. | $34.74 | 2022 | |
| Glaxosmithkline, LLC. | $34.23 | 2022-2023 | Shingrix, Fluarix Quadrivalent |
| Xeris Pharmaceuticals, INC. | $33.49 | 2022-2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.99 | 2020 | |
| Genentech USA, INC. | $21.05 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.24 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $17.47 | 2022 | |
| Merck Sharp & Dohme LLC | $15.01 | 2020 | |
| Allergan, INC. | $14.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.